Evidence map›Paper›PMID 36595537›Full record

ArticlePLoS computational biology2023

Deep-sequencing of viral genomes from a large and diverse cohort of treatment-naive HIV-infected persons shows associations between intrahost genetic diversity and viral load.

Migle Gabrielaite, Marc Bennedbæk, Malthe Sebro Rasmussen, Virginia Kan, Hansjakob Furrer, Robert Flisiak, Marcelo Losso, Jens D Lundgren, INSIGHT START Study Group, Rasmus L Marvig

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00867048 (Strategic Timing of AntiRetroviral Treatment), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00867048 phase4completednot on this map

Strategic Timing of AntiRetroviral Treatment

TypeinterventionalSponsorUniversity of MinnesotaRan2009 to 2022Enrolled4,688ConditionsHIV InfectionArmsAll licensed antiretroviral medications
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Migle GabrielaiteCenter for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-7959-8767
Marc BennedbækCentre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-2753-5991
Malthe Sebro RasmussenCenter for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-2982-6258
Virginia KanVeterans Affairs Medical Center and The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States of America.ORCID 0000-0001-7569-2740
Hansjakob FurrerDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0002-1375-3146
Robert FlisiakDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
Marcelo LossoHospital General De Agudos J M Ramos Mejía, Buenos Aires, Argentina.ORCID 0000-0002-4273-4833
Jens D LundgrenCentre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8901-7850
INSIGHT START Study Group
Rasmus L MarvigCenter for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-5267-3173
Rigshospitalet · DKUniversity of Copenhagen · DKGeorge Washington University · USHospital Ramos Mejía · ARMedical University of Białystok · PLUniversity of Bern · CH

Funding

International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)UM1AI068641 · NIAID · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2011 to 2014
$83.5M
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): STARTUM1AI120197 · NIAID · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2015 to 2017
$65.1M
Extended follow-up of randomized participants in the INSIGHT START trialU01AI136780 · NIAID · UNIVERSITY OF MINNESOTA · PI GRUND, BIRGIT, REILLY, CAVAN S. · 2019 to 2024
$18.0M
NIAID NIH HHS U01 AI136780NIAID NIH HHS UM1 AI068641NIAID NIH HHS UM1 AI120197
6 · The paper itself

Abstract

backgroundInfection with human immunodeficiency virus type 1 (HIV) typically results from transmission of a small and genetically uniform viral population. Following transmission, the virus population becomes more diverse because of recombination and acquired mutations through genetic drift and selection. Viral intrahost genetic diversity remains a major obstacle to the cure of HIV; however, the association between intrahost diversity and disease progression markers has not been investigated in large and diverse cohorts for which the majority of the genome has been deep-sequenced. Viral load (VL) is a key progression marker and understanding of its relationship to viral intrahost genetic diversity could help design future strategies for HIV monitoring and treatment.

methodsWe analysed deep-sequenced viral genomes from 2,650 treatment-naive HIV-infected persons to measure the intrahost genetic diversity of 2,447 genomic codon positions as calculated by Shannon entropy. We tested for associations between VL and amino acid (AA) entropy accounting for sex, age, race, duration of infection, and HIV population structure.

resultsWe confirmed that the intrahost genetic diversity is highest in the env gene. Furthermore, we showed that mean Shannon entropy is significantly associated with VL, especially in infections of >24 months duration. We identified 16 significant associations between VL (p-value<2.0x10-5) and Shannon entropy at AA positions which in our association analysis explained 13% of the variance in VL. Finally, equivalent analysis based on variation in HIV consensus sequences explained only 2% of VL variance.

conclusionsOur results elucidate that viral intrahost genetic diversity is associated with VL and could be used as a better disease progression marker than HIV consensus sequence variants, especially in infections of longer duration. We emphasize that viral intrahost diversity should be considered when studying viral genomes and infection outcomes.

trial registrationSamples included in this study were derived from participants who consented in the clinical trial, START (NCT00867048) (23), run by the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). All the participant sites are listed here: http://www.insight-trials.org/start/my_phpscript/participating.php?by=site.

Indexed as

HIV InfectionsDisease ProgressionGenetic VariationGenome, ViralHumansMutationViral Load

Identifiers

PMID36595537
PMCPMC9838853
OpenAlexW4313454697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.